Premium
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study *
Author(s) -
Marzano A.V.,
Genovese G.,
Casazza G.,
Moltrasio C.,
Dapavo P.,
Micali G.,
Sirna R.,
Gisondi P.,
Patrizi A.,
Dini V.,
Bianchini D.,
Bianchi L.,
Fania L.,
Prignano F.,
Offidani A.,
Atzori L.,
Bettoli V.,
Cannavò S.P.,
Venturini M.,
Bongiorno M. R.,
Costanzo A.,
Fabbrocini G.,
Peris K.
Publication year - 2021
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.18983
Subject(s) - adalimumab , medicine , hidradenitis suppurativa , dermatology life quality index , odds ratio , confidence interval , retrospective cohort study , quality of life (healthcare) , visual analogue scale , cohort , logistic regression , surgery , tumor necrosis factor alpha , disease , nursing
Summary Background The anti‐tumour necrosis factor ( TNF )‐α adalimumab is the only licenced biologic for moderate‐to‐severe hidradenitis suppurativa ( HS ). No predictors of response have been identified so far. Objectives To identify clinical parameters predicting response to adalimumab and confirm its efficacy/safety. Methods The data of 389 patients with HS treated with adalimumab in 21 Italian centres were reviewed. Sex, age at onset/diagnosis/baseline, body mass index, smoking, phenotype, previous treatments, concomitant antibiotics and ‘therapeutic delay’, defined as the time from HS onset to adalimumab initiation, were assessed. Response to adalimumab and its impact on quality of life (QoL) were evaluated using the Hidradenitis Suppurativa Clinical Response (Hi SCR ) and the Dermatology Life Quality Index ( DLQI ) or the Visual Analogue Scale for pain ( VAS pain), respectively. Logistic regression analysis was performed. Results The therapeutic delay correlated to lack of response to adalimumab at week 16 [odds ratio ( OR ) 1·92 for therapeutic delay > 10 years; 95% confidence interval ( CI ) 1·28–2·89; P = 0·0016). Hi SCR was achieved in 43·7% and 53·9% patients at week 16 and 52, respectively. Significant reductions in both DLQI and VAS pain were found between week 16 vs. baseline ( P < 0·0001 for both) and week 52 vs. baseline ( P < 0·0001 for both). Previous immunosuppressants inversely correlated to Hi SCR at week 52 ( OR = 1·74, 95% CI 1·04–2·91, P = 0·0342). Conclusions Inverse correlation between therapeutic delay and clinical response was found, supporting early adalimumab use and providing evidence for a ‘window of opportunity’ in HS treatment. Adalimumab efficacy and safety were confirmed, along with patients’ QoL improvement. Immunosuppressants could negatively influence the response to adalimumab inducing a switch to non‐ TNF ‐α‐driven pathways.